High-Density Lipoprotein Particle Number
HDL P
Description
"High-Density Lipoprotein (HDL) Particle Number" test measures how many HDL particles circulate in your blood, offering more detail than a basic HDL level. More particles typically mean better cholesterol transport and protection against plaque buildup. Doctors use this test to evaluate cardiovascular risk, especially when standard cholesterol readings are unclear. Low particle counts may suggest elevated heart risk. Results help shape strategies like dietary changes, medication, or exercise. Ongoing tracking improves heart disease prevention and long-term lipid health.
Test Category
Lipids, Proteins
Procedure
Invasive
Sample Type
Blood – Serum
Units
Micromoles Per Liter
Procedure Category
Blood Draw
Test Group
Complete Cardiovascular Group, Lipoprotein Fractionation Group
Test Group Description
Complete Cardiovascular Group: This group contains comprehensive tests for an extensive evaluation of cardiovascular health, providing thorough insights into heart-related conditions beyond basic assessments. Lipoprotein Fractionation Group: Analyzes lipoprotein fractions through NMR technology, providing detailed insights into lipid metabolism and cardiovascular health.
Optimal Range
For All Individuals:
Conventional Unit: 32.80–43.40 µmol/L
SI Unit: Not Applicable
Normal Range
For All Individuals:
Conventional Unit: 21.10–43.40 µmol/L
SI Unit: Not Applicable
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Alcohol consumption (Excessive intake of alcoholic beverages)
Cholestasis (Impaired bile flow from the liver)
Estrogen replacement therapy
Genetic factors (Inherited traits affecting HDL particle number)
Healthy fat consumption
Medications (such as nicotinic acid and fibrates)
...
Key Reasons For Testing
Enhanced Risk Assessment: HDL-P provides a detailed evaluation of cardiovascular risk, complementing traditional HDL-C measurements.
Subclass Analysis: Assesses HDL particle subclasses to understand their influence on cardiovascular health.
Dyslipidemia Evaluation: Stratifies risk in individuals with dyslipidemia by analyzing HDL size and composition.
Residual Risk Marker: Identifies ongoing cardiovascular risk despite controlled LDL-C levels.
Therapy Monitoring: Tracks HDL-P changes to evaluate the impact of lipid-lowering treatments and lifestyle adjustments.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle size and concentrations by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010;59(5):1153-1160.
[2] Matyus SP, Braun PJ, Wolak-Dinsmore J, et al. HDL particle number measured on the Vantera® Clinical Analyzer accurately predicts cardiovascular events in women: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Clin Chem. 2015;61(3):539-548.
[3] Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105-113.
[4] Superko HR, Gadesam RR. HDL: high-density lipoprotein particle size and subfraction distribution are major, independent, cardiovascular risk factors. J Cardiometab Syndr. 2008;3(6):380-385.
[5] Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: implications for LDL management. J Clin Lipidol. 2007;1(6):583-592.
[6] Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, factor VII, and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol.2012;32(9):2282-2290.
[7] Asztalos BF, Tani M, Schaefer EJ. Metabolic and functional relevance of HDL subspecies. Curr Opin Lipidol.2011;22(3):176-185.
[8] Rosenson RS, Brewer HB Jr, Ansell BJ, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48-60.
[9] Ko DT, Alter DA, Guo H, et al. High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study. J Am Coll Cardiol. 2016;68(19):2073-2083.
[10] Heinecke JW. The HDL proteome: a marker—and perhaps mediator—of coronary artery disease. J Lipid Res.2009;50(Suppl):S167-S171.
[11] Fleg JL, Mete M, Howard BV, et al. Effect of statin therapy on HDL cholesterol levels in older adults: results from the Cardiovascular Health Study. J Am Coll Cardiol. 2008;51(25):2514-2522.
[12] Mora S, Buring JE, Ridker PM. Association of high-density lipoprotein cholesterol with incident cardiovascular events in women by low-density lipoprotein cholesterol and apolipoprotein B100 levels: does size matter? Circulation.2011;124(22):2410-2417.
[13] Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127-135.
[14] Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006;58(3):342-374.
[15] Toth PP, Gotto AM, Rader DJ. High-density lipoproteins: therapeutic targeting and clinical applications. Nat Rev Drug Discov. 2014;13(8):593-609.